Why Benitec Biopharma Inc.’s (BNTC) Stock Is Up 6.91%
As of Tuesday, July 28, Benitec Biopharma Inc.’s BNTC share price has surged by 6.91%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.
Commentary & Analysis
Why Benitec Biopharma Inc.’s (BNTC) Stock Is Down 5.04%
As of Friday, July 10, Benitec Biopharma Inc.’s BNTC share price has dipped by 5.04%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Benitec Biopharma Inc.’s (BNTC) Stock Is Up 6.26%
As of Tuesday, June 23, Benitec Biopharma Inc.’s BNTC share price has surged by 6.26%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Benitec Biopharma Inc.’s (BNTC) Stock Is Up 6.62%
As of Wednesday, June 17, Benitec Biopharma Inc.’s BNTC share price has surged by 6.62%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Benitec Biopharma Inc.’s (BNTC) Stock Is Down 5.74%
As of Friday, May 15, Benitec Biopharma Inc.’s BNTC share price has dipped by 5.74%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | BNTC | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $463.1 | $292.6 | 36% |
|
| Shares Out (Mil) | 49.4 | 54.4 | 47% |
|
| Institutional Ownership | 95.5% | 93.2% | 67% |
|
| Float (Mil) | 17.9 | 40.2 | 27% |
|
| Beta | 0.28 | 0.94 | 17% |
|
| Avg Daily Volume (000s) | 276 | 544 | 49% |
|
| Price Change (52-week) |
4.7% | 59.7% | 48% |
|
| Growth | BNTC | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (35.5%) | (10.1%) | 11% |
|
| EPS (5yr) | 62.3% | 16.0% | 96 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | 15.0% | (15.6%) | 73% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | BNTC | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($42) | ($43) | 18% |
|
| EPS (TTM) | ($0.934) | ($1.400) | 22% |
|
| Operating Cash Flow (TTM) (Mil) | ($20) | ($31) | 15% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 14% |
|
| Enterprise Value (Q1) (Mil) | $223 | $164 | 27% |
|
| Valuation | BNTC | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.52 | 2.83 | 58% |
|
| P/E | na | 19.6 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | BNTC | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 64.2% | na |
|
| Net Margin | na | (75.9%) | na |
|
| ROA | (28.4%) | (47.5%) | 17% |
|
| ROE | (29.6%) | (55.0%) | 20% |
|
| Liabilities to Assets | 2.0% | 29.6% | 1% |
|
| F-Score | 4 | 3 | 33% |
|
Benitec Biopharma Inc. did not pass any screens on 8/21/2026.
